These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 15486858)

  • 1. Inconsistencies in reporting of granulomatous infectious diseases associated with infliximab and etanercept.
    Schaible TF
    Clin Infect Dis; 2004 Oct; 39(8):1255-6; author reply 1256. PubMed ID: 15486858
    [No Abstract]   [Full Text] [Related]  

  • 2. Granulomatous infectious diseases associated with tumor necrosis factor antagonists.
    Wallis RS; Broder MS; Wong JY; Hanson ME; Beenhouwer DO
    Clin Infect Dis; 2004 May; 38(9):1261-5. PubMed ID: 15127338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Granulomatous infections due to tumor necrosis factor blockade: correction.
    Wallis RS; Broder M; Wong J; Beenhouwer D
    Clin Infect Dis; 2004 Oct; 39(8):1254-5. PubMed ID: 15486857
    [No Abstract]   [Full Text] [Related]  

  • 4. Tuberculosis cases associated with infliximab and etanercept.
    Winthrop KL; Siegel JN
    Clin Infect Dis; 2004 Oct; 39(8):1256-7. PubMed ID: 15486859
    [No Abstract]   [Full Text] [Related]  

  • 5. Granulomatous lung disease occurring during etanercept treatment.
    Phillips K; Weinblatt M
    Arthritis Rheum; 2005 Aug; 53(4):618-20. PubMed ID: 16082636
    [No Abstract]   [Full Text] [Related]  

  • 6. Both etanercept and infliximab can elevate tumor necrosis factor (TNF)-alpha and be the cause of treatment related new onset disease: the need to measure circulating TNF-alpha.
    Kast RE; Altschuler EL
    J Rheumatol; 2008 Aug; 35(8):1679; author reply 1679-80. PubMed ID: 18671327
    [No Abstract]   [Full Text] [Related]  

  • 7. Focus on adverse events of tumour necrosis factor alpha blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients.
    Gerloni V; Pontikaki I; Gattinara M; Fantini F
    Ann Rheum Dis; 2008 Aug; 67(8):1145-52. PubMed ID: 17981916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reactivation of latent granulomatous infections by infliximab.
    Wallis RS; Broder M; Wong J; Lee A; Hoq L
    Clin Infect Dis; 2005 Aug; 41 Suppl 3():S194-8. PubMed ID: 15983899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Summaries for patients. Tumor necrosis factor antagonists and heart failure.
    Ann Intern Med; 2003 May; 138(10):I48. PubMed ID: 12755581
    [No Abstract]   [Full Text] [Related]  

  • 10. Infliximab (Remicade) adn etanercept (Enbrel): serious infections and tuberculosis.
    Dunlop H
    CMAJ; 2004 Oct; 171(8):992-3. PubMed ID: 15497208
    [No Abstract]   [Full Text] [Related]  

  • 11. Perforating folliculitis associated with tumour necrosis factor-alpha inhibitors administered for rheumatoid arthritis.
    Gilaberte Y; Coscojuela C; Vázquez C; Roselló R; Vera J
    Br J Dermatol; 2007 Feb; 156(2):368-71. PubMed ID: 17223880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TNF-alpha antagonists: pulmonary legionellosis.
    Prescrire Int; 2007 Feb; 16(87):20. PubMed ID: 17326282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medicare coverage of tumor necrosis factor alpha inhibitors as an influence on physicians' prescribing behavior.
    DeWitt EM; Glick HA; Albert DA; Joffe MM; Wolfe F
    Arch Intern Med; 2006 Jan; 166(1):57-63. PubMed ID: 16401811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Arthralgia as an adverse event to infliximab: a reactive arthritis or triggering of psoriatic arthritis? Successful management by switching to etanercept.
    Moustou AE; Stratigos AJ; Vergou T; Gregoriou S; Georgala S; Danopoulou I
    J Eur Acad Dermatol Venereol; 2009 Aug; 23(8):968-9. PubMed ID: 19207660
    [No Abstract]   [Full Text] [Related]  

  • 15. Tumor necrosis factor and granuloma biology: explaining the differential infection risk of etanercept and infliximab.
    Wallis RS; Ehlers S
    Semin Arthritis Rheum; 2005 Apr; 34(5 Suppl1):34-8. PubMed ID: 15852254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mathematical modeling of the cause of tuberculosis during tumor necrosis factor blockade.
    Wallis RS
    Arthritis Rheum; 2008 Apr; 58(4):947-52. PubMed ID: 18383389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Indications and adverse events with the use of anti-TNFalpha agents in pediatric rheumatology: experience of a single center].
    de Oliveira SK; de Almeida RG; Fonseca AR; Rodrigues MC; Sztajnbok F; Diniz C
    Acta Reumatol Port; 2007; 32(2):139-50. PubMed ID: 17572652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation.
    Galor A; Perez VL; Hammel JP; Lowder CY
    Ophthalmology; 2006 Dec; 113(12):2317-23. PubMed ID: 16996615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Severe fungal infections linked to drugs.
    Kuehn BM
    JAMA; 2008 Oct; 300(14):1639. PubMed ID: 18840827
    [No Abstract]   [Full Text] [Related]  

  • 20. Use of tumor necrosis factor-alpha inhibitors in patients with chronic hepatitis B infection.
    Carroll MB; Bond MI
    Semin Arthritis Rheum; 2008 Dec; 38(3):208-17. PubMed ID: 18221983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.